RU2011127334A - Лечение остеоартрита - Google Patents
Лечение остеоартрита Download PDFInfo
- Publication number
- RU2011127334A RU2011127334A RU2011127334/15A RU2011127334A RU2011127334A RU 2011127334 A RU2011127334 A RU 2011127334A RU 2011127334/15 A RU2011127334/15 A RU 2011127334/15A RU 2011127334 A RU2011127334 A RU 2011127334A RU 2011127334 A RU2011127334 A RU 2011127334A
- Authority
- RU
- Russia
- Prior art keywords
- subject
- csf
- antagonist
- antibody specific
- specified
- Prior art date
Links
- 201000008482 osteoarthritis Diseases 0.000 title claims abstract 3
- 229940121860 Granulocyte macrophage colony stimulating factor antagonist Drugs 0.000 claims abstract 6
- 102000004457 Granulocyte-Macrophage Colony-Stimulating Factor Human genes 0.000 claims abstract 4
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 claims abstract 4
- 239000005557 antagonist Substances 0.000 claims abstract 4
- 102000016355 Granulocyte-Macrophage Colony-Stimulating Factor Receptors Human genes 0.000 claims abstract 2
- 108010092372 Granulocyte-Macrophage Colony-Stimulating Factor Receptors Proteins 0.000 claims abstract 2
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/243—Colony Stimulating Factors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pain & Pain Management (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Virology (AREA)
- Polarising Elements (AREA)
- Glass Compositions (AREA)
- Crystals, And After-Treatments Of Crystals (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Abstract
1. Способ лечения остеоартрита у субъекта, включающий стадию введения субъекту эффективного количества антагониста гранулоцитарно-макрофагального колониестимулирующего фактора (GM-CSF).2. Способ по п.1, где указанный субъект представляет собой человека.3. Способ по п.1, где указанный субъект представляет собой мышь.4. Способ по п.1, где указанный антагонист представляет собой антитело, специфичное в отношении GM-CSF.5. Способ по п.1, где указанный антагонист представляет собой антитело, специфичное в отношении рецептора GM-CSF.
Claims (5)
1. Способ лечения остеоартрита у субъекта, включающий стадию введения субъекту эффективного количества антагониста гранулоцитарно-макрофагального колониестимулирующего фактора (GM-CSF).
2. Способ по п.1, где указанный субъект представляет собой человека.
3. Способ по п.1, где указанный субъект представляет собой мышь.
4. Способ по п.1, где указанный антагонист представляет собой антитело, специфичное в отношении GM-CSF.
5. Способ по п.1, где указанный антагонист представляет собой антитело, специфичное в отношении рецептора GM-CSF.
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US13967908P | 2008-12-22 | 2008-12-22 | |
| US61/139,679 | 2008-12-22 | ||
| US16448609P | 2009-03-30 | 2009-03-30 | |
| US61/164,486 | 2009-03-30 | ||
| PCT/AU2009/001672 WO2010071924A1 (en) | 2008-12-22 | 2009-12-21 | Osteoarthritis treatment |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2016102339A Division RU2712273C2 (ru) | 2008-12-22 | 2009-12-21 | Лечение остеоартрита |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2011127334A true RU2011127334A (ru) | 2013-01-27 |
Family
ID=42286786
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2016102339A RU2712273C2 (ru) | 2008-12-22 | 2009-12-21 | Лечение остеоартрита |
| RU2011127334/15A RU2011127334A (ru) | 2008-12-22 | 2009-12-21 | Лечение остеоартрита |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2016102339A RU2712273C2 (ru) | 2008-12-22 | 2009-12-21 | Лечение остеоартрита |
Country Status (19)
| Country | Link |
|---|---|
| US (4) | US9243061B2 (ru) |
| EP (2) | EP3056217B1 (ru) |
| JP (3) | JP5727379B2 (ru) |
| KR (2) | KR101898982B1 (ru) |
| CN (2) | CN102271705A (ru) |
| AU (1) | AU2009329814B2 (ru) |
| BR (1) | BRPI0918356B1 (ru) |
| CA (1) | CA2746827C (ru) |
| CY (1) | CY1117698T1 (ru) |
| DK (1) | DK2376121T4 (ru) |
| ES (2) | ES2572368T5 (ru) |
| HK (1) | HK1226938A1 (ru) |
| HR (1) | HRP20160577T4 (ru) |
| HU (1) | HUE028615T2 (ru) |
| PL (1) | PL2376121T5 (ru) |
| RU (2) | RU2712273C2 (ru) |
| SI (2) | SI2376121T2 (ru) |
| SM (1) | SMT201600156B (ru) |
| WO (1) | WO2010071924A1 (ru) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2978209T3 (es) | 2008-12-22 | 2024-09-09 | Univ Melbourne | Tratamiento del dolor |
| RU2712273C2 (ru) | 2008-12-22 | 2020-01-28 | Де Юниверсити Оф Мельбурн | Лечение остеоартрита |
| UA117228C2 (uk) | 2012-09-20 | 2018-07-10 | Морфосис Аґ | Фармацевтична композиція, що містить антитіло до gm-csf |
| DE102013222200A1 (de) * | 2013-10-31 | 2015-08-27 | Osram Opto Semiconductors Gmbh | Elektronisches Bauelement und Verfahren zum Herstellen eines elektronischen Bauelements |
| AU2018318425A1 (en) * | 2017-08-14 | 2020-02-27 | Zynerba Pharmaceuticals, Inc. | Methods of treatment of osteoarthritis with transdermal cannabidiol gel |
| WO2020104833A1 (en) * | 2018-11-19 | 2020-05-28 | 4P-Pharma | Composition and methods for regulating chondrocyte proliferation and increasing of cartilage matrix production |
| CN110075304B (zh) * | 2019-05-29 | 2020-02-11 | 四川大学华西医院 | 一种治疗骨关节炎的药物组合物及其用途 |
Family Cites Families (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5225539A (en) * | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| IL95061A0 (en) | 1989-07-14 | 1991-06-10 | Schering Corp | Antagonists of gm-csf derived from the carboxyl terminus |
| EP0486572B1 (en) | 1989-08-11 | 1998-01-07 | Amrad Corporation Limited | Improvements in granulocyte-macrophage colony-stimulating factor receptor and derivatives thereof |
| WO1994009149A1 (en) | 1990-08-10 | 1994-04-28 | Amrad Corporation Limited | Monoclonal antibody |
| WO1994011404A1 (en) | 1992-11-19 | 1994-05-26 | Dana-Farber Cancer Institute | Antibodies for gm-csf receptor and uses thereof |
| CA2229043C (en) | 1995-08-18 | 2016-06-07 | Morphosys Gesellschaft Fur Proteinoptimierung Mbh | Protein/(poly)peptide libraries |
| AUPP525198A0 (en) | 1998-08-13 | 1998-09-03 | Medvet Science Pty. Ltd. | Monoclonal antibody inhibitor of GM-CSF, IL-3 and IL-5 and other cytokines and uses thereof |
| US7108852B2 (en) | 2000-03-20 | 2006-09-19 | Warner-Lambert Company Llc | Methods of treating inflammation using antibodies to M-CSF |
| US7455836B2 (en) * | 2000-05-08 | 2008-11-25 | The University Of Melbourne | Method of treatment and agents useful for same |
| WO2003035048A2 (en) * | 2001-10-26 | 2003-05-01 | Novartis Ag | Methods for the treatment of osteoarthritis and compositions thereof |
| ES2365606T3 (es) | 2002-02-13 | 2011-10-07 | Ludwig Institute For Cancer Research Ltd. | Anticuerpos contra gm-csf quiméricos. |
| US20040241755A1 (en) * | 2003-06-02 | 2004-12-02 | Pfizer Inc. | Human cell assay to determine effect of sample compounds on Col2 enhancer expression |
| BRPI0506679A (pt) | 2004-02-11 | 2007-05-15 | Warner Lambert Co | métodos de tratar osteoartrite com antagonistas de il-6 |
| ES2465141T3 (es) * | 2004-03-31 | 2014-06-05 | Kazuwa Nakao | Remedio o medicamento preventivo para la artritis |
| EP1593690B1 (en) | 2004-05-05 | 2009-07-01 | Micromet AG | Preparation of ScFv antibody fragments |
| US7662573B2 (en) | 2004-08-18 | 2010-02-16 | The United States Of America As Represented By The Department Of Health And Human Services | Methods for evaluating osteoarthritis risk |
| US20060040258A1 (en) | 2004-08-23 | 2006-02-23 | Huiyan Guo | Water-soluble conjugates and methods of preparation |
| KR20150091193A (ko) | 2005-04-18 | 2015-08-07 | 암젠 리서치 (뮌헨) 게엠베하 | 인간 과립구 마크로파지 콜로니 자극 인자의 중화 항체 |
| BRPI0610796B8 (pt) * | 2005-05-18 | 2021-05-25 | Morphosys Ag | anticorpo humano ou humanizado isolado, ou um fragmento fab ou scfv do mesmo, sequência de ácidos nucleicos, vetor, e, uso de um anticorpo |
| JP4736037B2 (ja) | 2005-10-26 | 2011-07-27 | 株式会社イーベック | ヒトｇｍ−ｃｓｆに結合するヒトのモノクローナル抗体並びにその抗原結合部分 |
| EP1957537A2 (en) * | 2005-12-01 | 2008-08-20 | Domantis Limited | Competitive domain antibody formats that bind interleukin 1 receptor type 1 |
| RS55526B1 (sr) * | 2006-02-08 | 2017-05-31 | Morphotek Inc | Antigenski gm-csf peptidi i antitela gm-csf |
| CN101443360B (zh) * | 2006-03-27 | 2013-11-27 | 医学免疫有限公司 | Gm-csf受体结合元件 |
| US7741273B2 (en) | 2006-04-13 | 2010-06-22 | Warsaw Orthopedic, Inc. | Drug depot implant designs |
| CN105435223A (zh) * | 2006-11-21 | 2016-03-30 | 卡罗拜奥斯制药公司 | 使用gm-csf拮抗剂治疗慢性炎症疾病的方法 |
| WO2008080134A2 (en) * | 2006-12-22 | 2008-07-03 | Rigel Pharmaceuticals, Inc. | 4-amin0-2- (hetero) arylamino-5- (hetero) arylthiazoles useful as axl inhibitors |
| EP2160407A4 (en) | 2007-05-23 | 2011-07-27 | Crc For Asthma And Airways Ltd | NEUTRALIZING ANTIBODIES |
| TW200918553A (en) | 2007-09-18 | 2009-05-01 | Amgen Inc | Human GM-CSF antigen binding proteins |
| US20090163440A1 (en) * | 2007-09-26 | 2009-06-25 | Waddell David D | Ion-Channel Regulator Compositions and Methods of Using Same |
| EP2217626A4 (en) | 2007-11-12 | 2011-06-22 | Crc For Asthma And Airways Ltd | EPITOP FOR NEUTRALIZING ANTIBODIES |
| BRPI0820530A2 (pt) * | 2007-11-13 | 2015-06-16 | Boehringer Ingelheim Int | Anticorpos monoclonais que se ligam ao hgm-csf e composições medicinais compreendendo os mesmos |
| WO2009118662A2 (en) | 2008-03-24 | 2009-10-01 | Abbott Biotechnology Ltd. | Methods and compositions for treating bone loss |
| EA201001691A1 (ru) | 2008-04-28 | 2011-10-31 | Калобайос Фармасьютикалз, Инк. | Антитела к гранулоцитарно-макрофагальному колониестимулирующему фактору |
| RU2712273C2 (ru) * | 2008-12-22 | 2020-01-28 | Де Юниверсити Оф Мельбурн | Лечение остеоартрита |
| ES2978209T3 (es) | 2008-12-22 | 2024-09-09 | Univ Melbourne | Tratamiento del dolor |
| US8609101B2 (en) | 2009-04-23 | 2013-12-17 | Theraclone Sciences, Inc. | Granulocyte-macrophage colony-stimulating factor (GM-CSF) neutralizing antibodies |
-
2009
- 2009-12-21 RU RU2016102339A patent/RU2712273C2/ru active
- 2009-12-21 KR KR1020177032850A patent/KR101898982B1/ko active Active
- 2009-12-21 CA CA2746827A patent/CA2746827C/en active Active
- 2009-12-21 EP EP15194091.3A patent/EP3056217B1/en active Active
- 2009-12-21 CN CN2009801516359A patent/CN102271705A/zh active Pending
- 2009-12-21 KR KR1020117017015A patent/KR101799264B1/ko active Active
- 2009-12-21 CN CN201610822096.9A patent/CN106397591A/zh active Pending
- 2009-12-21 JP JP2011541030A patent/JP5727379B2/ja active Active
- 2009-12-21 RU RU2011127334/15A patent/RU2011127334A/ru unknown
- 2009-12-21 BR BRPI0918356-6A patent/BRPI0918356B1/pt active IP Right Grant
- 2009-12-21 WO PCT/AU2009/001672 patent/WO2010071924A1/en not_active Ceased
- 2009-12-21 US US13/140,467 patent/US9243061B2/en active Active
- 2009-12-21 HU HUE09833924A patent/HUE028615T2/en unknown
- 2009-12-21 EP EP09833924.5A patent/EP2376121B2/en active Active
- 2009-12-21 SI SI200931446T patent/SI2376121T2/sl unknown
- 2009-12-21 DK DK09833924.5T patent/DK2376121T4/da active
- 2009-12-21 AU AU2009329814A patent/AU2009329814B2/en active Active
- 2009-12-21 ES ES09833924T patent/ES2572368T5/es active Active
- 2009-12-21 HR HRP20160577TT patent/HRP20160577T4/hr unknown
- 2009-12-21 SI SI200931446A patent/SI2376121T1/sl unknown
- 2009-12-21 PL PL09833924T patent/PL2376121T5/pl unknown
- 2009-12-21 ES ES15194091T patent/ES2886063T3/es active Active
-
2015
- 2015-02-20 JP JP2015031198A patent/JP2015143233A/ja active Pending
- 2015-12-18 US US14/975,024 patent/US20160185868A1/en not_active Abandoned
-
2016
- 2016-05-18 CY CY20161100433T patent/CY1117698T1/el unknown
- 2016-06-01 SM SM201600156T patent/SMT201600156B/it unknown
- 2016-12-06 HK HK16113893.3A patent/HK1226938A1/en unknown
-
2017
- 2017-06-12 JP JP2017114806A patent/JP6458086B2/ja active Active
- 2017-11-13 US US15/811,279 patent/US20180066062A1/en not_active Abandoned
-
2020
- 2020-03-31 US US16/836,464 patent/US20200247895A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2011127333A (ru) | Лечение боли | |
| RU2011127334A (ru) | Лечение остеоартрита | |
| EA201690994A1 (ru) | Антагонисты активина-actriia и применение для стимуляции роста кости у больных раком | |
| RU2014117707A (ru) | Способ лечения пролиферативного заболевания | |
| MX385217B (es) | Antagonistas de actriib y dosificación y usos de los mismos. | |
| EA201000094A1 (ru) | Производные пиримидинил-пиридазинона | |
| RU2012110882A (ru) | Производные 6-аминохиназолина или 3-цианохинолина, способы их получения и их фармацевтические применения | |
| EA201200318A1 (ru) | Гетероциклические оксимы | |
| EA201200260A1 (ru) | Гетероциклические гидразоны и их применение для лечения рака и воспаления | |
| MX361458B (es) | Compuestos de pirimido-piridazinona y uso de los mismos. | |
| EA201590700A1 (ru) | Новый способ получения соединений для применения при лечении рака | |
| GEP20156319B (en) | Asymmetric ureas and medical uses thereof | |
| EA201100254A1 (ru) | Новые соединения | |
| EA201170425A1 (ru) | Тетрациклиновые соединения для лечения ревматоидного артрита и связанные с ними способы лечения | |
| EA200970764A1 (ru) | Способ лечения расстройств, вызванных пролиферацией клеток, с применением стимуляторов секреции гормона роста | |
| BR112013002441A2 (pt) | uso de um anticorpo anti-cd20 afucosilado, composição e método de tratamento de paciente que sofre de câncer | |
| EA201390755A1 (ru) | БЕНЗОКСАЗЕПИНЫ КАК ИНГИБИТОРЫ PI3K/mTOR И СПОСОБЫ ИХ ИСПОЛЬЗОВАНИЯ И ПРОИЗВОДСТВА | |
| JP2012512815A5 (ru) | ||
| RU2010141793A (ru) | Терапевтические замещенные циклопентаны | |
| CY1106131T1 (el) | Θepαπευτικη αγωγη της μασταλγιας με 4-υδροξυ ταμοξιφενη | |
| MX2007006355A (es) | Epitopes antigenos de interleucina-21, anticuerpos relacionados y su uso en el campo medico. | |
| AR081514A1 (es) | El compuesto 4-[etil(dimetil)amonio]butanoato, el metodo para la preparacion del mismo y el uso en el tratamiento de la enfermedad cardiovascular | |
| EA201390530A1 (ru) | Способ получения сополимера натрийкарбоксиметилцеллюлозы и госсипола и его применение в комплексной терапии пациентов с аутистическими расстройствами и когнитивными нарушениями | |
| EA201390314A1 (ru) | Супернатант, кондиционированный активированными лейкоцитами, и его использование для заживления ран | |
| EA201270390A1 (ru) | 1,2,4-триазин, который может быть использован в качестве ускорителя вулканизации, и способ его получения |